(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2014 (14.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/124423 A1

(51) International Patent Classification:
A61K 39/145 (2006.01) *A61K 39/155* (2006.01)

(21) International Application Number:
PCT/US2014/015725

(22) International Filing Date:
11 February 2014 (11.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/763,309 11 February 2013 (11.02.2013) US
61/875,327 9 September 2013 (09.09.2013) US

(72) Inventors; and
(71) Applicants : **SMITH, Gale E.** [US/US]; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). **GLENN, Greg** [US/US]; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). **FRIES, Lou** [US/US]; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US). **YOUNG, James F.** [US/US]; c/o Novavax, Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878 (US).

(74) Agents: **TUSCAN, Michael** et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, District of Columbia 20004-2400 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: COMBINATION VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS AND INFLUENZA

Fig .1 RSV F AND TRIVALENT FLU VLP COMBINATION VACCINE



- S205 Monovalent Bulk Vaccine formulations were used to prepare Trivalent Flu VLP
- A/California/07/09, A/Victoria/210/09, B/Wisconsin/1/10 strains were used
- RSV F nanoparticle vaccine from a development lot 683.15p was used in combination vaccine

(57) **Abstract**: The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory synctial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.

WO 2014/124423 A1